Patsy Carney, co-founder and CEO of EirGen Pharma, tells us the strategy behind their 2015 acquisition by US-based OPKO Health, the highlights of their current transformation from an Irish CDMO business to a center of excellence in R&D and supply chain for the Group, the new sterile, oral solid dose and dry powder inhalation capabilities their new R&D center in Waterford will have, and his priorities for the next few years.
Patsy, what have been the highlights of the past year, since EirGen Pharma was acquired by the US-based OPKO Health in May 2015?
"For the past 17 months then, EirGen has been in a state of transformation. Our core business prior to the acquisition would have been as a classic CDMO with exports to 45 countries of our out-licensed products."
